Claims for Patent: 10,525,104

✉ Email this page to a colleague

Summary for Patent: 10,525,104

Title:	Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
Abstract:	The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.
Inventor(s):	Sims; Tasha Nicholle (New York, NY), Gao; Bo (Ringoes, NJ), Lowy; Israel (Dobbs Ferry, NY)
Assignee:	REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)
Application Number:	15/509,461
Patent Claims:	1. A method for treating metastatic colorectal cancer (mCRC), the method comprising administering a VEGF antagonist to a patient, wherein the VEGF antagonist is a VEGF Trap that comprises Ig-like domain 2 of VEGFR1, Ig-like domain 3 of VEGFR2, and a multimerizing domain, wherein the patient has been diagnosed with mCRC and has been selected for treatment with the VEGF antagonist on the basis of exhibiting elevated expression of VEGF-A; wherein the elevated expression of VEGF-A is determined based on a comparison to the lower level of VEGF-A in subjects with mCRC. 2. The method of claim 1, wherein the VEGF Trap is ziv-aflibercept. 3. The method of claim 2, further comprising administering to the subject a chemotherapeutic regimen comprising irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI).

Details for Patent 10,525,104

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	⤷ Get Started Free	2035-09-10
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	⤷ Get Started Free	2035-09-10
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	August 03, 2012	⤷ Get Started Free	2035-09-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.